

# TALK COVID, TALK PAXLOVID

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.<sup>1</sup>

## Paxlovid Coverage Information

Paxlovid is available on the BC PharmaCare Formulary and covered under Plan Z for B.C. residents with active Medical Services Plan (MSP) coverage with the following criteria for adults who are:

- Moderate-to-severely immunocompromised, and/or
- 60 years or older with a high-risk chronic condition

For more information on eligibility, please visit <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/paxlovid-information-for-health-professionals>.

### Private insurance coverage for PAXLOVID

Paxlovid is covered by 96% of private insurance plans with no special authorization form\*. No pre-approval is necessary.

\*Data on File, Pfizer Canada ULC





Use the eForm to prescribe  
OR VISIT URL

[www2.gov.bc.ca/assets/gov/  
health/forms/2368fil.pdf](http://www2.gov.bc.ca/assets/gov/health/forms/2368fil.pdf)

Please consult the Product Monograph at <http://pfizer.ca/pm/en/paxlovid.pdf> for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.

**Reference: 1.** PAXLOVID Product Monograph. Pfizer Canada ULC. August 14, 2024.



**Paxlovid™**  
(nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)

© 2025 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5  
PAXLOVID™ Pfizer Inc., Pfizer Canada ULC, Licensee  
PP-C1D-CAN-0032-EN

